Venmax Drugs & Pharmaceuticals Fair Value
Venmax Drugs & Pharmaceuticals (VENMAX) average fair value is ₹16.2 across 3 valuation models — P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, vs a current market price of ₹23.96 (-32.4%), fair value range ₹6.53–₹30.39. See VENMAX price to book ratio to compare market price against book value per share.
Fair Value Analysis Export
VENMAX Fair Value vs Current Price — Valuation Summary
VENMAX average fair value, fair value range, price gap and valuation status across 3 models: P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation. For live price and a broader fundamental view, visit Venmax Drugs & Pharmaceuticals share price screener.
P/B Based Valuation
Price-to-Sales Valuation
Asset-Based Valuation
VENMAX Fair Value Analysis — Data Sources & Coverage
Venmax Drugs & Pharmaceuticals financial data sources, valuation methods applied and sector benchmarks used — 2025 financial year. Also explore Venmax Drugs & Pharmaceuticals stock price data download to track price trends across different timeframes.
Available Data Sources: Financial statements, balance sheet data , sector comparisons.
Data Currency: Financial data is from the previous year (2025).
VENMAX vs Healthcare Sector Peers — P/E, P/B & Market Cap
Venmax Drugs & Pharmaceuticals P/E ratio, P/B ratio and market capitalisation vs Healthcare sector peers — relative valuation comparison.
| Company | Symbol | P/E Ratio | P/B Ratio | Market Cap (₹ Cr) |
|---|---|---|---|---|
| Murae Organisor | MURAE | 2.86 | 0.2 | ₹41 |
| Accretion Pharmaceuticals | ACCPL | 17.91 | 2.7 | ₹120 |
| Jeena Sikho Lifecare | JSLL | 40.38 | 23.07 | ₹7,944 |
| Par Drugs & Chemical | PAR | 8.2 | 0.96 | ₹103 |
| Aurobindo Pharma | AUROPHARMA | 25.16 | 2.5 | ₹87,806 |
Important Disclaimer
This fair value analysis is for informational and educational purposes only. The calculations are based on publicly available financial data and various valuation methodologies.
This analysis does not constitute investment advice, recommendations, or suggestions to buy, sell, or hold any securities. Past performance and financial data do not guarantee future results.
Please conduct your own research and consult with qualified financial advisors before making any investment decisions. Market conditions, company fundamentals, and other factors can significantly impact actual stock performance.